-
Heavy! The world's first new drug to delay type 1 diabetes was approved by the FDA
Time of Update: 2023-01-06
The approval is based on a randomized, double-blind, event-driven, placebo-controlled trial of 76 patients with stage 2 diabetes who evaluated the safety and efficacy of Teplizumab.
The approval is based on a randomized, double-blind, event-driven, placebo-controlled trial of 76 patients with stage 2 diabetes who evaluated the safety and efficacy of Teplizumab.
-
On the second anniversary of the "dual carbon" goal, how can Chinese pharmaceutical companies move towards carbon neutrality?
Time of Update: 2023-01-06
For Chinese pharmaceutical companies, judging and adapting to the specific impacts of climate change on their business and industrial chains, and promoting the sustainability of carbon reduction measures by improving resilience and resilience, is an important starting point for them to achieve their long-term carbon neutrality goals.
-
The market value soared 243%, and Immunocore and TCR therapy went against the current
Time of Update: 2023-01-05
As the world's first TCR therapy approved for marketing, Kimmtrak did not disappoint Immunocore, and its rising sales led to higher market expectations for the company.
As the world's first TCR therapy approved for marketing, Kimmtrak did not disappoint Immunocore, and its rising sales led to higher market expectations for the company.
-
The FDA appears to be tightening expedited approval requirements: confirmation testing is required at the time of filing
Time of Update: 2023-01-05
ADC Therapeutics said Nov. 8 in its third-quarter earnings report, "At the FDA After providing strong guidance to reconsider the accelerated approval pathway, the company is going back in time to re-evaluate its experimental novel antibody conjugate (ADC) Cami (camidanlumab) targeting CD25 tesirine）。 The FDA's guidance is that randomized confirmatory Phase 3 studies must proceed smoothly and preferably be fully enrolled at the time of submission of the BLA application.
-
The FDA Commissioner talks to the Director of the Oncology Center of Excellence to discuss several hot topics
Time of Update: 2023-01-05
[1] The Commissioner of the FDA and the Director of the Oncology Center of Excellence comment on hot regulatory topics[2] The Center for Drug Evaluation of the State Food and Drug Administration of Ch
-
This biotech with "only 6 full-time employees" is about to IPO, can it be more "small and beautiful"?
Time of Update: 2023-01-05
com/） Company official website Company official website #EXECUTIVE_DIRECTOR_COMPENSATION #EXECUTIVE_DIRECTOR_COMPENSATION Other publicly available information Other publicly available information Since disease treatment entered the era of immunotherapy, T cells have become the focus of new drug developers, if the definition of "target" is expanded, T cells will undoubtedly be the hottest target in the past 20 years.
-
Chinese pharmaceutical companies have accelerated their overseas expansion, and a number of new drug clinical applications have been accepted by the FDA
Time of Update: 2023-01-05
At present, the overseas expansion of Chinese pharmaceutical companies continues to accelerate, and affected by this, it has recently been reported that a number of domestic new drug clinical trial applications have been accepted by the FDA.
-
Lianhua Qingwen rose by more than 50%! Yiling Pharmaceutical's response: Nothing; Anhui and Guangdong nucleic acid testing prices "shall not go up, and there is no limit to downward adjustments"
Time of Update: 2023-01-05
(Oriental Wealth) According to foreign media, three people familiar with the matter said that the World Health Organization is planning to rename monkeypox to "M pox" (MPOX) in order to free the virus from stigma.
-
A picture to understand Several policies and measures for Shanghai to accelerate the construction of a global biomedical R&D economy and industrialization highland
Time of Update: 2023-01-05
Encourage the physical operation of biomedical R&D centers, introduce and cultivate innovative headquarters, improve the incubation and cultivation mechanism of science and technology enterprises, optimize support policies such as R&D and production, strengthen the guidance of fiscal funds to social capital, further increase the total economic contribution of Shanghai biomedical R&D, and build a global biomedical R&D economy and industrialization highland.
-
Latest! Forecast of the 8th batch of nationally harvested varieties (with list of enterprises)
Time of Update: 2023-01-05
Attached: Forecast of the eighth batch of nationally harvested varietiesAttached: Forecast of the eighth batch of nationally harvested varieties Source: Yilian Recruitment Network In terms of rules, the industry has also called for certain changes.
-
After the license in/out spree, who decides the subsequent patents?
Time of Update: 2023-01-05
Pharmaceutical companies need to develop drug lifecycle strategies to effectively manage and use external patents in open innovation projects.
Pharmaceutical companies need to develop drug lifecycle strategies to effectively manage and use external patents in open innovation projects.
-
The efficacy is not good, and the world's first in vivo gene editing therapy presses the pause button
Time of Update: 2023-01-05
Nowadays, many big names in the medical field are trying to modify and modify specific target genes of the human genome based on CRISPR technology, and from in vitro editing to in vivo editing, the steps are getting bigger and bigger.
-
Yuan Jianwei: In the next journey of innovative drug investment, we must first be clear about "whose money you want to make"
Time of Update: 2023-01-05
Yuan Jianwei:Vertex Ventures China Fund China) In 2008, it began to make China's technology investment, and in 2013, in the era of vigorous Internet e-commerce, Vertex instead laid out a lithium metal battery start-up company SES, when the public was not very clear about the future of lithium metal batteries, Vertex has in-depth research and forward-looking judgment on the development of the new energy industry, and attaches great importance to the founder's deep technical accumulation in this project.
-
The Swing of Azvudine: Between Lianhua Qingwen and Paxlovid
Time of Update: 2023-01-05
As a soon-to-be-listed company, the first test of commercialization is so broken -02- -02-Behind the Stop keyBehind the Stop keyIn fact, in July this year, consumers also found in the mini program of an online pharmacy that another approved new crown oral drug Pfizer P drug in China was on the shelves.
-
More contagious and escapeous! The Omicron variant has mutated again!
Time of Update: 2023-01-05
7 variant are mainly manifested as high fever, persistent cough, body aches, headache, sore throat, olfactory changes and loss of appetite, which are similar to those after infection with the early Omicron subtype variant of the new crown.
-
Series serialization| Overseas wayfinding, the next decade of China's local pharmaceutical companies (1)
Time of Update: 2023-01-05
) ）GBI (click to read)"Combo punch" attack: overseas mode and market selectionInspiration and reflection: a voyage that "opens up a different way"As the first part of this series, this article will analyze the drivers and trends of innovative pharmaceutical companies going global.
-
When is the downturn going on? Three ways to help pharmaceutical companies withstand the "cold winter"
Time of Update: 2023-01-05
3 ways pharma can weather a recession； pharmavoice Increased product sales and deals can only partially shield pharmaceutical companies from the winds of a harsh recession, rather than focus on reducing costs, especially at a time of rising inflation.
-
Review of China's hospital pharmaceutical market in the third quarter of 2022
Time of Update: 2023-01-05
From the quarterly sales of the product In the third quarter of 2022, China's hospital pharmaceutical market has recovered, but it still decreased slightly year-on-year, and the total sales* quarterly growth rate was -0.
-
Pharmaceutical companies have been continuously reporting drug reviews in the past few days!
Time of Update: 2023-01-05
According to public information, the concentrated solution for tirofiban hydrochloride for injection is a Class B variety of national medical insurance in 2021, and in 2021, the sales of the drug in China will be about 170 million yuan.
-
$178 million boost! Targeting multiple druggable targets, the cutting-edge development of "first-in-class" peptide therapy
Time of Update: 2023-01-05
”English: _mstmutation="1" _msthash="220727" _msttexthash="2606149">English:On November 21, FogPharma announced the completion of a $178 million Series D funding round to advance its pipeline of first-in-class spiral peptide therapies targeting key cancer drivers.
